NewsVandana Singh
BillionToOne
BLLN · NASDAQ
$103.50+$2.47 (+2.44%)TodayMarket closed ·
Prev close $101.03
Latest news
- Press releasePRNewswire
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Press releasePRNewswire
BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
- NewsAvi Kapoor
Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'
- Press releasePRNewswire
/C O R R E C T I O N -- BillionToOne/
- Press releasePRNewswire
Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsTanya Rawat
BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
BillionToOne Q3 EPS $0.15 Misses $0.19 Estimate, Sales $109.400M Beat $109.365M Estimate
- Press releasePRNewswire
BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar
- Press releasePRNewswire
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
- Press releaseGlobe Newswire
BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
- NewsAvi Kapoor
Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care Stock
- News
Earnings Scheduled For May 6, 2026
- News
BillionToOne Q2 EPS $0.34 Beats $0.04 Estimate, Sales $108.388M Beat $96.885M Estimate
- Press releasePRNewswire
BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics
- NewsAvi Kapoor
Joby Aviation Is 'Too Risky,' But This Industrial Stock Is A 'Winner': Jim Cramer
- Press releasePRNewswire
BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
- News
BillionToOne Q4 EPS $0.11 Beats $0.03 Estimate, Sales $96.053M Beat $87.161M Estimate.
- Press releasePRNewswire
BillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®
- Press releasePRNewswire
BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal Care
- Press releasePRNewswire
BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare
- Press releasePRNewswire
BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East
- Press releaseGlobe Newswire
BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Press releasePRNewswire
BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair
- NewsAvi Kapoor
This Joby Aviation Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
- Press releasePRNewswire
Gunderson Dettmer Represents Long-Time Client BillionToOne in its Upsized $273.1 Million Initial Public Offering
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.